Five years ago, psychedelic stocks were among the hottest stories in biotechnology.
Investors poured money into companies developing treatments based on psilocybin, MDMA and other psychedelic compounds. Venture capital flowed into the sector, retail traders chased the next big breakthrough, and analysts predicted psychedelic medicines would create an entirely new pharmaceutical category worth billions of dollars.
Then the market turned.
Rising interest rates reduced investor appetite for speculative growth companies, capital became harder to access, and clinical development timelines proved longer than many investors had anticipated. By late 2023, many psychedelic stocks had lost more than 80 per cent of their value. Several companies disappeared through restructures, mergers or insolvencies, while others survived only by dramatically cutting costs and narrowing their focus.
To many observers, the psychedelic boom looked like another pandemic-era investment bubble that had finally burst.
Yet while investors were abandoning the sector, the science continued moving forward. Researchers kept conducting trials, patients continued enrolling in studies, and regulators continued reviewing emerging data. Unlike many speculative industries that flourished during the same period, psychedelic medicine continued producing something tangible: evidence.
That evidence is beginning to change the conversation.
Today, investors are increasingly looking beyond the hype cycle and focusing on a more practical question. If psychedelic therapies become approved treatments, which companies are best positioned to commercialise them successfully?
Compass Pathways: Chasing the First Approval
No company better represents the evolution of the psychedelic sector than Compass Pathways.
When Compass listed on the NASDAQ in 2020, it quickly became the face of psychedelic investing. Supporters viewed the company as a future pharmaceutical leader, while critics questioned whether psychedelic therapies could ever satisfy the regulatory requirements needed for mainstream medicine.
Several years later, Compass remains one of the industry’s strongest contenders. Its lead program, COMP360, a synthetic psilocybin treatment for treatment-resistant depression, has progressed further through clinical development than any modern psilocybin therapy.
The significance extends well beyond Compass itself. Treatment-resistant depression affects millions of people worldwide and remains one of psychiatry’s most difficult challenges. Existing antidepressants often take weeks to work, can produce significant side effects, and fail to provide adequate relief for many patients.
If COMP360 ultimately receives regulatory approval, it would represent more than a victory for a single company. It would validate an entirely new therapeutic category and demonstrate that psychedelic medicines can successfully navigate modern regulatory systems, attract reimbursement and generate commercial revenue within mainstream healthcare.
In biotechnology, that kind of validation can transform an entire industry.
Cybin: Building More Scalable Therapies
While Compass has attracted much of the attention, Cybin has quietly emerged as one of the sector’s most closely watched companies.
Rather than focusing solely on naturally occurring psychedelic compounds, Cybin is developing modified molecules designed to retain therapeutic benefits while reducing treatment duration. The strategy addresses one of the industry’s most significant commercial challenges: scalability.
Many psychedelic-assisted therapy sessions require six to eight hours of clinician supervision. That creates substantial staffing, infrastructure and cost requirements that could limit widespread adoption. Shorter treatment durations have the potential to reduce costs, increase patient throughput and make psychedelic therapies more practical for healthcare systems operating under pressure.
Cybin’s approach reflects a broader shift taking place throughout the industry. The first generation of psychedelic companies focused on proving these therapies could work. Increasingly, the next generation is focused on proving they can work at scale.
For investors, that distinction could prove critical. The long-term winners may not necessarily be the companies with the most promising compounds, but the companies that can deliver treatments efficiently and profitably.
MindMed: From Speculation to Execution
Few companies better illustrate the boom-and-bust cycle of psychedelic investing than MindMed.
At the height of the sector’s popularity, MindMed became a favourite among retail investors seeking exposure to the emerging psychedelic market. Its valuation soared as enthusiasm reached fever pitch.
When sentiment reversed, however, the company’s share price suffered heavily. Management changes, strategic uncertainty and broader market weakness combined to make MindMed a symbol of the sector’s excesses.
Today, the story looks very different.
The company has narrowed its strategic focus, strengthened its leadership and continued advancing its clinical programs. More importantly, investors are increasingly evaluating MindMed using the same framework applied to other biotechnology companies. Rather than being viewed primarily as a speculative narrative, it is now judged on clinical progress, regulatory milestones and commercial potential.
That shift may not generate the same excitement as the speculative boom years, but it represents something far more important: credibility.
GH Research: The Short-Duration Bet
Among the industry’s emerging contenders, GH Research stands out for its focus on 5-MeO-DMT, one of the most powerful psychedelic compounds known.
Unlike psilocybin, which can produce experiences lasting several hours, 5-MeO-DMT therapies may offer significantly shorter treatment durations. If proven effective, that characteristic could create substantial advantages from both a clinical and commercial perspective.
A therapy that requires less clinician supervision and shorter treatment sessions could be easier to integrate into existing healthcare settings. For providers, insurers and governments, the economics become considerably more attractive.
This is why GH Research has attracted increasing investor attention. The company is not simply developing another psychedelic treatment. It is attempting to solve one of the industry’s most important practical questions: how can psychedelic therapies become scalable healthcare products rather than niche specialist services?
The answer could have implications well beyond a single company.
Atai Life Sciences: A Portfolio Approach
Most biotechnology companies are built around a single lead asset.
Atai Life Sciences has chosen a different path.
Founded by entrepreneur Christian Angermayer and backed by technology investor Peter Thiel, the company has assembled a diversified portfolio spanning multiple psychedelic and non-psychedelic mental health technologies.
The strategy resembles a venture capital fund operating within a publicly listed company. Rather than relying on one breakthrough, Atai spreads risk across numerous programs and technologies. Some will inevitably fail, while others may succeed.
For institutional investors, that diversification can be attractive. It provides exposure to the broader mental health innovation space without requiring a single clinical outcome to determine the company’s future.
As the psychedelic industry matures, portfolio-based models such as Atai’s may become increasingly appealing.
Why Institutions Are Returning
Perhaps the most important story in the sector is not occurring inside laboratories.
It is occurring inside investment committees.
For years, many professional investors viewed psychedelic medicine as too controversial, too speculative or too early-stage to justify meaningful exposure. Today, those concerns are gradually beginning to fade.
Clinical evidence continues to accumulate. Regulatory agencies are engaging more actively with developers. Manufacturing standards have improved, and commercial pathways are becoming clearer. The route from laboratory research to approved treatment is still challenging, but it is becoming increasingly visible.
As a result, institutional investors are beginning to evaluate psychedelic companies using the same criteria applied across the broader biotechnology industry. Questions around market size, reimbursement, manufacturing capability and competitive positioning are becoming more important than debates over whether psychedelic therapies have scientific merit.
That shift represents a significant milestone in the industry’s development.
Australia’s Strategic Position
Australia occupies a unique position in the global psychedelic landscape.
In 2023, the country became the first to establish a national regulatory pathway allowing authorised psychiatrists to prescribe both psilocybin and MDMA for specific mental health conditions. While patient numbers remain relatively modest, the decision attracted international attention and positioned Australia as an important testing ground for psychedelic-assisted therapies.
Companies involved in manufacturing, clinical delivery, therapist training and patient care now have an opportunity to develop expertise that could become increasingly valuable as larger markets move toward similar regulatory frameworks.
Australian organisations including Emyria, Bioxyne and a growing network of specialist clinics are helping build the infrastructure required to support the emerging industry. If larger jurisdictions such as the United States eventually approve psychedelic medicines, Australia’s early experience may prove to be a meaningful competitive advantage.
The Road Ahead
The psychedelic industry still faces considerable risks.
Clinical failures remain possible. Regulatory delays remain likely. Commercial adoption could occur more slowly than many investors hope, while reimbursement pathways remain uncertain in several jurisdictions.
Yet the sector entering 2027 bears little resemblance to the speculative market that dominated headlines earlier this decade.
The surviving companies are generally stronger, more disciplined and increasingly focused on execution. Clinical evidence continues to improve, regulatory pathways are becoming clearer and investors are paying greater attention to commercial realities than promotional narratives.
For years, critics argued that psychedelic medicine was an interesting idea searching for proof. Today, the industry has accumulated enough evidence to shift the conversation.
The debate is increasingly centred on implementation, commercialisation and competition.
The question is no longer whether psychedelic companies can attract attention from investors. The question is which companies will successfully transform promising science into sustainable healthcare businesses.
That may ultimately determine who wins the next chapter of the psychedelic industry.
